BGB-DXP593

DRUG2 trials

Sponsors

BeiGene

Conditions

Covid19Healthy

Phase 1

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

CompletedNCT04669262

Start: 2020-12-09End: 2021-05-21Updated: 2024-10-26

Phase 2

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

CompletedNCT04551898

Start: 2020-12-02End: 2021-05-25Updated: 2024-10-26

Related Papers

SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial.

2023-02-162 citations